Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.130
-0.020 (-0.48%)
At close: Apr 1, 2026, 4:00 PM EDT
4.130
0.00 (0.00%)
After-hours: Apr 1, 2026, 4:31 PM EDT
Aquestive Therapeutics Employees
Aquestive Therapeutics had 147 employees as of December 31, 2025. The number of employees increased by 5 or 3.52% compared to the previous year.
Employees
147
Change (1Y)
5
Growth (1Y)
3.52%
Revenue / Employee
$303,027
Profits / Employee
-$569,959
Market Cap
504.05M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 147 | 5 | 3.52% |
| Dec 31, 2024 | 142 | 7 | 5.19% |
| Dec 31, 2023 | 135 | 5 | 3.85% |
| Dec 31, 2022 | 130 | -27 | -17.20% |
| Dec 31, 2021 | 157 | -30 | -16.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,842 |
| Canopy Growth | 960 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 854 |
| Kamada | 462 |
| Esperion Therapeutics | 294 |
| Akebia Therapeutics | 194 |
| Ironwood Pharmaceuticals | 100 |
AQST News
- 6 days ago - AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt - PRNewsWire
- 12 days ago - Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. - GlobeNewsWire
- 19 days ago - Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation - Seeking Alpha
- 20 days ago - AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt - PRNewsWire
- 21 days ago - Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval - Seeking Alpha
- 23 days ago - Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - GlobeNewsWire
- 26 days ago - AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Aquestive Therapeutics - Business Wire